1. Home
  2. MESO vs SPNS Comparison

MESO vs SPNS Comparison

Compare MESO & SPNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • SPNS
  • Stock Information
  • Founded
  • MESO 2004
  • SPNS 1982
  • Country
  • MESO Australia
  • SPNS Israel
  • Employees
  • MESO N/A
  • SPNS N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • SPNS Computer Software: Prepackaged Software
  • Sector
  • MESO Health Care
  • SPNS Technology
  • Exchange
  • MESO Nasdaq
  • SPNS Nasdaq
  • Market Cap
  • MESO 1.4B
  • SPNS 1.5B
  • IPO Year
  • MESO N/A
  • SPNS 1992
  • Fundamental
  • Price
  • MESO $10.97
  • SPNS $28.39
  • Analyst Decision
  • MESO Buy
  • SPNS Buy
  • Analyst Count
  • MESO 4
  • SPNS 4
  • Target Price
  • MESO $18.00
  • SPNS $34.25
  • AVG Volume (30 Days)
  • MESO 156.4K
  • SPNS 185.0K
  • Earning Date
  • MESO 02-26-2025
  • SPNS 05-08-2025
  • Dividend Yield
  • MESO N/A
  • SPNS 3.40%
  • EPS Growth
  • MESO N/A
  • SPNS 11.11
  • EPS
  • MESO N/A
  • SPNS 1.30
  • Revenue
  • MESO $5,670,000.00
  • SPNS $544,235,000.00
  • Revenue This Year
  • MESO $152.37
  • SPNS $4.49
  • Revenue Next Year
  • MESO $336.12
  • SPNS $5.15
  • P/E Ratio
  • MESO N/A
  • SPNS $21.79
  • Revenue Growth
  • MESO N/A
  • SPNS 3.84
  • 52 Week Low
  • MESO $5.78
  • SPNS $23.69
  • 52 Week High
  • MESO $22.00
  • SPNS $41.22
  • Technical
  • Relative Strength Index (RSI)
  • MESO 44.34
  • SPNS 58.57
  • Support Level
  • MESO $10.77
  • SPNS $27.47
  • Resistance Level
  • MESO $11.61
  • SPNS $29.90
  • Average True Range (ATR)
  • MESO 0.47
  • SPNS 0.79
  • MACD
  • MESO 0.09
  • SPNS 0.18
  • Stochastic Oscillator
  • MESO 27.68
  • SPNS 63.35

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About SPNS Sapiens International Corporation N.V. (Cayman Islands)

Sapiens International Corp NV is a provider of software solutions for the insurance industry, with an emerging focus on the financial services sector. The company offers software, solutions, and professional services for property & casualty (P&C); reinsurance; life, pension & annuity (L&A); workers' compensation (WC); medical professional liability (MPL); financial & compliance (F&C); and decision modeling for both insurance and financial markets. The group also provides services for project delivery and implementation services, for its Software Solutions portfolio. Geographically, it operates in the region of North America, Rest of the World, and Europe. It generates revenue from Europe.

Share on Social Networks: